Thomas Keane to Humans
This is a "connection" page, showing publications Thomas Keane has written about Humans.
Connection Strength
0.475
-
Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Curr Urol Rep. 2017 Jun; 18(6):41.
Score: 0.022
-
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol. 2013 Dec; 31(6):1327-32.
Score: 0.016
-
Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun; 109 Suppl 6:1-12.
Score: 0.015
-
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate. Urology. 2010 Nov; 76(5):1162-7.
Score: 0.014
-
The multi-disciplinary management of high-risk prostate cancer. Urol Oncol. 2012 Jan-Feb; 30(1):3-15.
Score: 0.013
-
Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence. BJU Int. 2009 Feb; 103(3):327-31.
Score: 0.012
-
Perineal prostatectomy in the age of minimally invasive surgery. J Ark Med Soc. 2008 Sep; 105(3):67-8.
Score: 0.012
-
Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology. 2008 Jun; 71(6):1177-80.
Score: 0.011
-
Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology. 2007 Dec; 70(6):1222.e9-11.
Score: 0.011
-
Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol. 2007 Dec; 14 Suppl 1:2-9.
Score: 0.011
-
Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm. Can J Urol. 2007 Dec; 14 Suppl 1:24-7.
Score: 0.011
-
Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma. Urology. 2005 Nov; 66(5):1110.
Score: 0.010
-
Partial segmental thrombosis of corpus cavernosum: case report and review of world literature. Urology. 2005 Jul; 66(1):194.
Score: 0.010
-
Bladder cancer--resection/ablation. Surg Oncol Clin N Am. 2005 Apr; 14(2):321-52.
Score: 0.009
-
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess. Urology. 2004 Oct; 64(4):808-10.
Score: 0.009
-
Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. Nucleosides Nucleotides Nucleic Acids. 2004; 23(1-2):291-306.
Score: 0.009
-
PC-SPES withdrawal response. Acta Oncol. 2004; 43(8):772-3.
Score: 0.009
-
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560.
Score: 0.007
-
Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV. Can J Urol. 2020 10; 27(5):10352-10362.
Score: 0.007
-
Comparison of Urologist- vs Gastroenterologist-Directed Extracorporeal Shock Wave Lithotripsy for Pancreaticolithiasis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1234-1239.
Score: 0.007
-
Mapping and Analysis of US State and Urban Local Sodium Reduction Laws. J Public Health Manag Pract. 2020 Mar/Apr; 26 Suppl 2, Advancing Legal Epidemiology:S62-S70.
Score: 0.007
-
Embryology, anatomy, and surgical applications of the kidney and ureter. Surg Clin North Am. 2000 Feb; 80(1):381-401, xiv.
Score: 0.007
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data. J Urol. 2020 Apr; 203(4):743-750.
Score: 0.006
-
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 04; 201(4):682-692.
Score: 0.006
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
Score: 0.006
-
Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system. J Urol. 1998 Jul; 160(1):252-6.
Score: 0.006
-
Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol. 2018 06; 36(6):310.e7-310.e13.
Score: 0.006
-
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 05; 35(5):183-191.
Score: 0.005
-
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Jun; 104:150-159.
Score: 0.005
-
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-na?ve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683.
Score: 0.005
-
Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. Urology. 2016 Apr; 90:32-7.
Score: 0.005
-
Conservative renal surgery. Has it a role in renal cell carcinoma? Surg Oncol Clin N Am. 1995 Apr; 4(2):295-306.
Score: 0.005
-
Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97.
Score: 0.005
-
Methoxypsoralen phototherapy of transitional cell carcinoma. Urology. 1994 Dec; 44(6):842-6.
Score: 0.005
-
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
Score: 0.004
-
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. Am J Clin Oncol. 2014 Apr; 37(2):188-93.
Score: 0.004
-
Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res. 1994 Jan 15; 54(2):475-81.
Score: 0.004
-
Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9.
Score: 0.004
-
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
Score: 0.004
-
Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences. J Sex Med. 2013 Dec; 10(12):3135-43.
Score: 0.004
-
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
Score: 0.004
-
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1?year after diagnosis: an economic perspective. Support Care Cancer. 2013 Dec; 21(12):3461-9.
Score: 0.004
-
Editorial comment. Urology. 2012 Sep; 80(3):563.
Score: 0.004
-
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health. 2012 Jul-Aug; 15(5):716-23.
Score: 0.004
-
Editorial comment. Urology. 2012 Jul; 80(1):168.
Score: 0.004
-
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul; 97(7):2315-24.
Score: 0.004
-
The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer. J Urol. 1991 Nov; 146(5):1418-24.
Score: 0.004
-
Contemporary diagnosis and management of squamous cell carcinoma (SCC) of the penis. BJU Int. 2011 Nov; 108(9):1378-92.
Score: 0.004
-
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):872-8.
Score: 0.004
-
Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. Int J Cancer. 2012 Jul 01; 131(1):158-64.
Score: 0.004
-
Penile cancer: an analysis of socioeconomic factors at a southeastern tertiary referral center. Can J Urol. 2011 Feb; 18(1):5524-8.
Score: 0.004
-
Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011 Sep; 108(6):851-6; discussion 856-7.
Score: 0.004
-
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 Apr; 59(4):543-52.
Score: 0.003
-
Autophagy is increased in prostate cancer cells overexpressing acid ceramidase and enhances resistance to C6 ceramide. Prostate Cancer Prostatic Dis. 2011 Mar; 14(1):30-7.
Score: 0.003
-
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011 Feb; 29(1):3-9.
Score: 0.003
-
Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. J Urol. 1990 Oct; 144(4):1004-9.
Score: 0.003
-
Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones. South Med J. 2010 Jun; 103(6):505-8.
Score: 0.003
-
Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010 May 01; 16(5):e121-30.
Score: 0.003
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.003
-
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
Score: 0.003
-
Assessing the gene space in draft genomes. Nucleic Acids Res. 2009 Jan; 37(1):289-97.
Score: 0.003
-
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008 Sep 15; 123(6):1357-63.
Score: 0.003
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
Score: 0.003
-
Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8.
Score: 0.003
-
Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol. 2007 Oct; 85(1):7-16.
Score: 0.003
-
Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008 Feb; 45(3):839-48.
Score: 0.003
-
Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11(1):46-52.
Score: 0.003
-
Inferior vena cava reconstruction using fresh inferior vena cava allograft following caval resection for leiomyosarcoma: midterm results. J Vasc Surg. 2007 Jul; 46(1):140-3.
Score: 0.003
-
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
Score: 0.003
-
A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2007 Jun; 51(6):1606-15.
Score: 0.003
-
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
Score: 0.003
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
Score: 0.003
-
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc. 2006 Aug; 102(7):241-9.
Score: 0.003
-
Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol. 2006 Jun; 175(6):2312-6.
Score: 0.003
-
Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice. BJU Int. 2005 Dec; 96(9):1280-5.
Score: 0.002
-
[Reevaluation of MAB therapy and progress of endocrine therapy]. Gan To Kagaku Ryoho. 2005 May; 32(5):705-28.
Score: 0.002
-
The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23.
Score: 0.002
-
Experience with coapted gastric tube outlet and composite gastrointestinal reservoir for continent cutaneous urinary diversion. J Urol. 2004 Jan; 171(1):229-31.
Score: 0.002
-
Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma. J Vasc Surg. 2003 Sep; 38(3):446-50.
Score: 0.002
-
Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft. Urol Oncol. 2003 Jan-Feb; 21(1):49-57.
Score: 0.002
-
Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002 Aug; 60(2):201-8.
Score: 0.002
-
Diuretic renogram in a patient with a urinary diversion: avoiding a false-positive diagnosis of obstruction with an indwelling catheter. Clin Nucl Med. 2001 Jul; 26(7):631-2.
Score: 0.002
-
Gunshot wounds to the ureter: a 40-year experience at Grady Memorial Hospital. J Urol. 2001 Jul; 166(1):119-21.
Score: 0.002
-
Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol. 2000 Dec; 13(12):1315-23.
Score: 0.002
-
Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000 Aug; 86(3):203-7.
Score: 0.002
-
pT1 urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol. 2000 Jan; 7(1):13-25.
Score: 0.002
-
Evaluation of staging lymphadenectomy in prostate cancer. Urology. 1998 Oct; 52(4):663-7.
Score: 0.001
-
Two cases of vasculitis of the urinary bladder: diagnostic and pathogenetic considerations. Arch Pathol Lab Med. 1998 Oct; 122(10):903-6.
Score: 0.001
-
Enhanced control by radiotherapy of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 1997 Aug 01; 39(1):149-54.
Score: 0.001
-
Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology. 1995 Aug; 46(2):200-4.
Score: 0.001
-
Outcome following radiotherapy in verrucous carcinoma of the larynx. Int J Radiat Oncol Biol Phys. 1995 Jun 15; 32(3):611-7.
Score: 0.001
-
Gastric cancer: the case for a more selective policy in surgical management. J R Coll Surg Edinb. 1993 Aug; 38(4):208-12.
Score: 0.001
-
Use of protective plastic sheath for prostatic biopsy. Urology. 1992 Jan; 39(1):88-9.
Score: 0.001
-
Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid. Int J Cancer. 1990 Aug 15; 46(2):238-44.
Score: 0.001
-
Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. Urol Res. 1990; 18(4):245-50.
Score: 0.001
-
Prostate-specific antigen. Superior serum marker for prostatic carcinoma. Ir J Med Sci. 1987 May; 156(5):138-41.
Score: 0.001